Prosecution Insights
Last updated: April 19, 2026
Application No. 18/552,718

COMPOSITION FOR IMPROVING BLOOD CHOLESTEROL LEVEL

Non-Final OA §102
Filed
Sep 27, 2023
Examiner
ABDALHAMEED, MANAHIL MIRGHANI ALI
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Suntory Holdings Limited
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
2y 4m
To Grant
90%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allow Rate
64 granted / 129 resolved
-10.4% vs TC avg
Strong +41% interview lift
Without
With
+40.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
45 currently pending
Career history
174
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
41.5%
+1.5% vs TC avg
§102
19.1%
-20.9% vs TC avg
§112
17.1%
-22.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 129 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This Application filed on 09/27/2023, is a National Stage Entry of International Patent Application No. PCT/JP2022/014243, filed 03/25/2022, which claims the priority of Japan patent application JP2021-074318 filed on 04/26/2021. Information Disclosure Statement The information disclosure statement (IDS) filed on 09/27/2023, 03/31/2025, and 05/19/2025, complies with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609. Accordingly, it has been placed in the application file and the information therein has been considered as to the merits, except where noted. Status of claims The preliminary amendment filed on 05/27/2025, that canceled claims 1-7, and 9, and added claim 10, is acknowledged. Claims 8, and 10 are pending. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. § 102 Rejection over Beelman Claims 8 and 10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by R. Beelman et al. (US PG Pub 2010/076093 A1, 03/25/2010, “Beelman” cited in the IDS dated 09/27/2023). Claim 10 is rejected over Beelman as evidenced by Lucaris, (Jun 24, 2019, lucariscrystal.com/pouring-the-perfect-glass-of-wine). Beelman discloses methods of maintaining and improving overall health of human by administration L-ergothioneine, [0015], [0019]. Beelman discloses that L-ergothioneine which naturally occurs in red wine, reduces the production of LDL, low density lipoprotein cholesterol and increasing HDL, high density lipoprotein cholesterol. [0021]. Therefore, Beelman anticipates claim 8. With regard to claim 10, Beelman discloses that in the wine making process sulfur dioxide is added in an amount of 260 mg/lit to reduce oxidation and preserve wine during storage and fermentation. Beelman discloses that all sulfur dioxide added to wine are replaced with L-ergothioneine. [0029]. Thus, the amount of L-ergothioneine added is 260 mg/Lit. As evidenced by Lucaris, one cup of wine is equivalent to 150 mL. Therefore, The amount of L-ergothioneine in one cup of wine (150 mL cup) is calculated to be 39 mg (260mg/1000mL * 150 mL = 39 mg of L-ergothioneine). 39 mg L-ergothioneine anticipates the range recited in claim 10 of 2-50 mg L-ergothioneine per day. § 102 Rejection over Abidin Claims 8 and 10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by M. Abidin, et al. (2017), International Journal of Food Properties, 20(6), 1251–1261, “Abidin” cited in the IDS dated 03/31/2025). Abidin discloses a method of reducing LDL, the bad cholesterol, and elevating the level of HDL, the good cholesterol by administering 5%(w/w) of Pleurotus ostreatus, wherein Pleurotus ostreatus is administered to human, [Pg. 1257, last para., pg. 1258, 2nd para.]. Abidin discloses that ergothioneine was identified in large amount in Pleurotus ostreatus with 118.91 mg/kg. [Pg. 1256, last para.]. Therefore, Abidin anticipates claim 8. 5%(w/w) of Pleurotus ostreatus = 5.95 mg of ergothioneine (5% w/w Pleurotus ostreatus of 1 kg Pleurotus ostreatus = 5/100 * 1000g = 50 kg Pleurotus ostreatus. 118.91 mg ergothioneine /1kg Pleurotus ostreatus * 50 kg Pleurotus ostreatus = 5.95 mg ergothioneine). Therefore, 5.95 mg ergothioneine anticipates claim 10 of 2-50 mg ergothioneine. Conclusion Claims 8 and 10 are rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MANAHIL MIRGHANI ALI ABDALHAMEED whose telephone number is (571)272-1242. The examiner can normally be reached M-F 7:30 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /M.M.A./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Sep 27, 2023
Application Filed
May 27, 2025
Response after Non-Final Action
Dec 14, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600728
INTERLEUKIN-17 INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Patent 12599607
PHARMACEUTICAL COMPOSITIONS COMPRISING TIMOLOL
2y 5m to grant Granted Apr 14, 2026
Patent 12600737
BIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12569183
Method of Administering Sotalol IV/SWITCH
2y 5m to grant Granted Mar 10, 2026
Patent 12559464
QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
90%
With Interview (+40.8%)
2y 4m
Median Time to Grant
Low
PTA Risk
Based on 129 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month